Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» non-small cell lung cancer
non-small cell lung cancer
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Flag link:
Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec
Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec
Fierce Pharma
AstraZeneca
Imfinzi
lung cancer
non-small cell lung cancer
Flag link:
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
Fierce Pharma
Eagle Pharmaceuticals
Pemfexy
Eli Lilly
mesothelioma
non-small cell lung cancer
Flag link:
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
BioSpace
Mirati Therapeutics
clinical trials
M&A
non-small cell lung cancer
sitravantinib
Flag link:
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Flag link:
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Fierce Pharma
Roche
Tecentriq
clinical trials
non-small cell lung cancer
Flag link:
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
Fierce Pharma
GSK
Merck
Jemperli
Keytruda
clinical trials
non-small cell lung cancer
Flag link:
Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease
Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease
Fierce Biotech
Gilead Sciences
Arcus Biosciences
clinical trials
domvanalimab
zimberelimab
non-small cell lung cancer
Flag link:
Lyvgen and BMS partner for Phase II lung cancer antibody trial
Lyvgen and BMS partner for Phase II lung cancer antibody trial
Clinical Trials Arena
Lyvgen
Bristol Myers Squibb
clinical trials
LVGN7409
non-small cell lung cancer
Flag link:
AZ claims another Imjudo approval, in big first-line NSCLC market
AZ claims another Imjudo approval, in big first-line NSCLC market
Pharmaphorum
AstraZeneca
FDA
Imjudo
non-small cell lung cancer
Flag link:
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Flag link:
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Fierce Biotech
Gilead Sciences
ARCUS
clinical trials
Merck
Keytruda
domvanalimab
zimberelimab
non-small cell lung cancer
Flag link:
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Endpoints
Daiichi Sankyo
AstraZeneca
Enhertu
breast cancer
non-small cell lung cancer
Flag link:
Nuvalent reports positive data from Phase I/II NSCLC therapy trial
Nuvalent reports positive data from Phase I/II NSCLC therapy trial
Clinical Trials Arena
Nuvalent
non-small cell lung cancer
NVL-520
clinical trials
Flag link:
GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement
GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement
Fierce Biotech
GSK
lung cancer
clinical trials
cobolimab
non-small cell lung cancer
Flag link:
FDA Approves Avastin Biosimilar for Six Types of Cancer
FDA Approves Avastin Biosimilar for Six Types of Cancer
Pharmacy Times
FDA
biosimilars
Vegzelma
Avastin
non-small cell lung cancer
glioblastoma
metastatic colorectal cancer
cervical caner
metastatic renal cell carcinoma
Flag link:
FDA panel votes against Spectrum's lung cancer drug
FDA panel votes against Spectrum's lung cancer drug
Reuters
FDA
Spectrum Pharrmaceuticals
non-small cell lung cancer
poziotinib
Flag link:
Amgen’s Phase 3 win in lung cancer puts pressure on Mirati bid for speedy FDA nod
Amgen’s Phase 3 win in lung cancer puts pressure on Mirati bid for speedy FDA nod
MedCity News
Amgen
Lumakras
non-small cell lung cancer
clinical trials
Flag link:
Genprex to progress Phase I/II trial of non-small cell lung cancer therapy
Genprex to progress Phase I/II trial of non-small cell lung cancer therapy
Clinical Trials Arena
Genprex
clinical trials
Reqorsa
AstraZeneca
Tagrisso
non-small cell lung cancer
Flag link:
FDA converts Novartis' NSCLC drug to a full approval with confirmatory data
FDA converts Novartis' NSCLC drug to a full approval with confirmatory data
Endpoints
Novartis
Tabrecta
solid tumors
FDA
non-small cell lung cancer
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »